Overexpressed FOXO4 inhibited the migration and metastasis of CRC cells by enhancing the APC2/β-catenin axis, suggesting that FOXO4 is a potential therapeutic target of CRC [132]. Here, FOXO4 is linked to colorectal carcinoma.